Cargando…
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent ne...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556690/ https://www.ncbi.nlm.nih.gov/pubmed/34746725 http://dx.doi.org/10.1016/j.eclinm.2021.101174 |
_version_ | 1784592219798241280 |
---|---|
author | Lau, Eric HY Hui, David SC Tsang, Owen TY Chan, Wai-Hung Kwan, Mike YW Chiu, Susan S Cheng, Samuel MS Ko, Ronald LW Li, John KC Chaothai, Sara Tsang, Chi H Poon, Leo LM Peiris, Malik |
author_facet | Lau, Eric HY Hui, David SC Tsang, Owen TY Chan, Wai-Hung Kwan, Mike YW Chiu, Susan S Cheng, Samuel MS Ko, Ronald LW Li, John KC Chaothai, Sara Tsang, Chi H Poon, Leo LM Peiris, Malik |
author_sort | Lau, Eric HY |
collection | PubMed |
description | BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent neutralizing antibody titre. METHODS: We collected sera from a cohort of 124 individuals with RT-PCR confirmed SARS-CoV-2 infections from Prince of Wales Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital and Queen Mary Hospitals of the Hospital Authority of Hong Kong, for periods up to 386 days after symptom onset and tested these for antibody to SARS-CoV-2 using 50% virus plaque reduction neutralization tests (PRNT(50)), surrogate neutralization tests and spike receptor binding domain (RBD) binding antibody. Patients were recruited from 21 January 2020 to 16 February 2021 and follow-up samples were collected until 9th March 2021. FINDINGS: Because the rate of antibody waning slows with time, we fitted lines of decay to 115 sera from 62 patients collected beyond 90 days after symptom onset and estimate that PRNT(50) antibody will remain detectable for around 1,717 days after symptom onset and that levels conferring 50% protection will be maintained for around 990 days post-symptom onset, in symptomatic patients. This would potentially be affected by emerging virus variants. PRNT titres wane faster in children. There was a high level of correlation between PRNT(50) antibody titers and the % of inhibition in surrogate virus neutralization tests. INTERPRETATION: The data suggest that symptomatic COVID-19 disease is followed by relatively long-lived protection from re-infection by antigenically similar viruses. FUNDING: Health and Medical Research Fund, Commissioned research on Novel Coronavirus Disease (COVID-19) (Reference Nos. COVID190126 and COVID1903003) from the Food and Health Bureau and the Theme-based Research Scheme project no. T11–712/19-N, the University Grants Committee of the Hong Kong SAR Government. |
format | Online Article Text |
id | pubmed-8556690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85566902021-11-01 Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection Lau, Eric HY Hui, David SC Tsang, Owen TY Chan, Wai-Hung Kwan, Mike YW Chiu, Susan S Cheng, Samuel MS Ko, Ronald LW Li, John KC Chaothai, Sara Tsang, Chi H Poon, Leo LM Peiris, Malik EClinicalMedicine Research paper BACKGROUND: The duration of immunity in SARS-CoV-2 infected people remains unclear. Neutralizing antibody responses are the best available correlate of protection against re-infection. Recent studies estimated that the correlate of 50% protection from re-infection was 20% of the mean convalescent neutralizing antibody titre. METHODS: We collected sera from a cohort of 124 individuals with RT-PCR confirmed SARS-CoV-2 infections from Prince of Wales Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital and Queen Mary Hospitals of the Hospital Authority of Hong Kong, for periods up to 386 days after symptom onset and tested these for antibody to SARS-CoV-2 using 50% virus plaque reduction neutralization tests (PRNT(50)), surrogate neutralization tests and spike receptor binding domain (RBD) binding antibody. Patients were recruited from 21 January 2020 to 16 February 2021 and follow-up samples were collected until 9th March 2021. FINDINGS: Because the rate of antibody waning slows with time, we fitted lines of decay to 115 sera from 62 patients collected beyond 90 days after symptom onset and estimate that PRNT(50) antibody will remain detectable for around 1,717 days after symptom onset and that levels conferring 50% protection will be maintained for around 990 days post-symptom onset, in symptomatic patients. This would potentially be affected by emerging virus variants. PRNT titres wane faster in children. There was a high level of correlation between PRNT(50) antibody titers and the % of inhibition in surrogate virus neutralization tests. INTERPRETATION: The data suggest that symptomatic COVID-19 disease is followed by relatively long-lived protection from re-infection by antigenically similar viruses. FUNDING: Health and Medical Research Fund, Commissioned research on Novel Coronavirus Disease (COVID-19) (Reference Nos. COVID190126 and COVID1903003) from the Food and Health Bureau and the Theme-based Research Scheme project no. T11–712/19-N, the University Grants Committee of the Hong Kong SAR Government. Elsevier 2021-10-30 /pmc/articles/PMC8556690/ /pubmed/34746725 http://dx.doi.org/10.1016/j.eclinm.2021.101174 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Lau, Eric HY Hui, David SC Tsang, Owen TY Chan, Wai-Hung Kwan, Mike YW Chiu, Susan S Cheng, Samuel MS Ko, Ronald LW Li, John KC Chaothai, Sara Tsang, Chi H Poon, Leo LM Peiris, Malik Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title | Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title_full | Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title_fullStr | Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title_full_unstemmed | Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title_short | Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection |
title_sort | long-term persistence of sars-cov-2 neutralizing antibody responses after infection and estimates of the duration of protection |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556690/ https://www.ncbi.nlm.nih.gov/pubmed/34746725 http://dx.doi.org/10.1016/j.eclinm.2021.101174 |
work_keys_str_mv | AT lauerichy longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT huidavidsc longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT tsangowenty longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT chanwaihung longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT kwanmikeyw longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT chiususans longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT chengsamuelms longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT koronaldlw longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT lijohnkc longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT chaothaisara longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT tsangchih longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT poonleolm longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection AT peirismalik longtermpersistenceofsarscov2neutralizingantibodyresponsesafterinfectionandestimatesofthedurationofprotection |